In:
Muscle & Nerve, Wiley, Vol. 26, No. 4 ( 2002-10), p. 549-552
Abstract:
We initiated a randomized, double‐blinded, placebo‐controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6‐week open‐label study of IVIG, positive trends were observed. © 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 549–552, 2002
Type of Medium:
Online Resource
ISSN:
0148-639X
,
1097-4598
Language:
English
Publisher:
Wiley
Publication Date:
2002
detail.hit.zdb_id:
1476641-3
SSG:
12
Permalink